Catalogue Number: AB02054-23.0-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | ITGB2; MFI7; Integrin beta-2; Cell surface adhesion glycoproteins LFA-1/CR3/p150.95 subunit beta; Complement receptor C3 subunit beta; β2-subunit of leukocyte integrins |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Rabbit |
| Clone: | H52 |
| Isotype: | IgG |
| Immunogen: | The original antibody was generated by immunizing BALB/c mice with human splenic adherent cells and later boosted with the same type of cells. |
| Application: | FC, IP, Blk, Inh |
ITGB2
P05107
3689
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
This antibody is successfully capable of inhibiting T cell, natural killer cells and complement receptor type 3 functions. Binding specificity of this antibody was confirmed with immunoprecipitation (PMID: 2580022). H52 mAb blocked 8E5-PHA-blast fusion in a dose-dependent manner with complete inhibition observed at concentrations above 3 µg/ml. Cell fusion (syncytium formation) is a major cytopathic effect of infection by human immunodeficiency virus (HIV). To determine the effect of the mAb on syncytium formation the LFA-1 expression of 8E5 cells and PHA-blasts was checked by flow cytometry. This mAb inhibited HIV-induced syncytium formation, however it did not block binding of gp120 to CD4 (PMID: 2543075). This mAb cross reacts with procine LFA-1 and profoundly inhibited mitogenic and allogenic stimulation of porcine T lymphocytes as well as cytotoxic T cell and natural killer (NK) cell function (PMID: 2481234). The expression of H52 epitope on beta-2 subunit isdependent on its interation with different alpha subunits of the leukocyte integrin LFA-1, Mac-1 and p150,95 and presence of calcium ions. The expression of the H52 epitope was examined by immunoprecipitation (PMID: 9808198).
This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.